Andreas Franke
Research Subjects
Andreas Franke has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
A Lubinski
1 shared publicationA Stanley
1 shared publication- Andreas Metzner
Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany
1 shared publication - Arcadi García-Alberola
Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain
1 shared publication - Ausias Garrigos
Space Power & Electronic Systems (SPES), Miguel Hernández University of Elche, 03202 Elche, Spain
1 shared publication B Schumacher
1 shared publication
Latest Publications
- Open Access
- 17 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Aerospace and Electronic Systems
- Vol. 60 (1) , 421-429
Sequential Switching Shunt Regulation Using DC Transformers for Solar Array Power Processing in High Voltage Satellites
This paper proposes a solar array regulation technique for a high-voltage satellite power bus. The regulation method combines on-off control at low frequency, i.e. kHz range, of highly efficient isolated and unregulated dc-dc converters operating at high frequency, i.e. hundreds of kHz. Although this technique can adopt different implementations, this paper deals with a hysteretic voltage control loop at low frequency, also known (Sequential Switching Shunt Regulator - S3R), and unregulated, isolated, current-fed, zero-voltage and zero-current push-pull dc-dc converters. Design guidelines and experimental validation are provided.
- 17 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Aerospace and Electronic Systems
- Vol. 60 (1) , 421-429
Open AccessSequential Switching Shunt Regulation Using DC Transformers for Solar Array Power Processing in High Voltage Satellites
This paper proposes a solar array regulation technique for a high-voltage satellite power bus. The regulation method combines on-off control at low frequency, i.e. kHz range, of highly efficient isolated and unregulated dc-dc converters operating at high frequency, i.e. hundreds of kHz. Although this technique can adopt different implementations, this paper deals with a hysteretic voltage control loop at low frequency, also known (Sequential Switching Shunt Regulator - S3R), and unregulated, isolated, current-fed, zero-voltage and zero-current push-pull dc-dc converters. Design guidelines and experimental validation are provided.
- Open Access
- 14 June 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (9) , 1313-1324
Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation
To evaluate the effectiveness and safety of cryoballoon ablation (CBA) compared with radiofrequency ablation (RFA) for symptomatic paroxysmal or drug-refractory persistent atrial fibrillation (AF). Prospective cluster cohort study in experienced CBA and RFA centres. Primary endpoint was ‘atrial arrhythmia recurrence’, secondary endpoints were as follows: procedural results, safety, and clinical course. A total of 4189 patients were included: CBA 2329 (55.6%) and RFA 1860 (44.4%). Cryoballoon ablation population was younger, with fewer comorbidities. Procedure time was longer in the RFA group (P = 0.01). Radiation exposure was 2487 (CBA) and 1792 cGycm2 (RFA) (P < 0.001). Follow-up duration was 441 (CBA) and 511 days (RFA) (P < 0.0001). Primary endpoint occurred in 30.7% (CBA) and 39.4% patients (RFA) [adjusted hazard ratio (adjHR) 0.85, 95% confidence interval (CI) 0.70–1.04; P = 0.12). In paroxysmal AF, CBA resulted in a lower risk of recurrence (adjHR 0.80, 95% CI 0.64–0.99; P = 0.047). In persistent AF, the primary outcome was not different between groups. Major adverse cardiovascular and cerebrovascular event rates were 1.0% (CBA) and 2.8% (RFA) (adjHR 0.53, 95% CI 0.26–1.10; P = 0.088). Re-ablations (adjHR 0.46, 95% CI 0.34–0.61; P < 0.0001) and adverse events during follow-up (adjHR 0.64, 95% CI 0.48–0.88; P = 0.005) were less common after CBA. Higher rehospitalization rates with RFA were caused by re-ablations. The primary endpoint did not differ between CBA and RFA. Cryoballoon ablation was completed rapidly; the radiation exposure was greater. Rehospitalization due to re-ablations and adverse events during follow-up were observed significantly less frequently after CBA than after RFA. Subgroup analysis suggested a lower risk of recurrence after CBA in paroxysmal AF. ClinicalTrials.gov (NCT01360008), https://clinicaltrials.gov/ct2/show/NCT01360008.
- 14 June 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (9) , 1313-1324
Open AccessOutcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation
To evaluate the effectiveness and safety of cryoballoon ablation (CBA) compared with radiofrequency ablation (RFA) for symptomatic paroxysmal or drug-refractory persistent atrial fibrillation (AF). Prospective cluster cohort study in experienced CBA and RFA centres. Primary endpoint was ‘atrial arrhythmia recurrence’, secondary endpoints were as follows: procedural results, safety, and clinical course. A total of 4189 patients were included: CBA 2329 (55.6%) and RFA 1860 (44.4%). Cryoballoon ablation population was younger, with fewer comorbidities. Procedure time was longer in the RFA group (P = 0.01). Radiation exposure was 2487 (CBA) and 1792 cGycm2 (RFA) (P < 0.001). Follow-up duration was 441 (CBA) and 511 days (RFA) (P < 0.0001). Primary endpoint occurred in 30.7% (CBA) and 39.4% patients (RFA) [adjusted hazard ratio (adjHR) 0.85, 95% confidence interval (CI) 0.70–1.04; P = 0.12). In paroxysmal AF, CBA resulted in a lower risk of recurrence (adjHR 0.80, 95% CI 0.64–0.99; P = 0.047). In persistent AF, the primary outcome was not different between groups. Major adverse cardiovascular and cerebrovascular event rates were 1.0% (CBA) and 2.8% (RFA) (adjHR 0.53, 95% CI 0.26–1.10; P = 0.088). Re-ablations (adjHR 0.46, 95% CI 0.34–0.61; P < 0.0001) and adverse events during follow-up (adjHR 0.64, 95% CI 0.48–0.88; P = 0.005) were less common after CBA. Higher rehospitalization rates with RFA were caused by re-ablations. The primary endpoint did not differ between CBA and RFA. Cryoballoon ablation was completed rapidly; the radiation exposure was greater. Rehospitalization due to re-ablations and adverse events during follow-up were observed significantly less frequently after CBA than after RFA. Subgroup analysis suggested a lower risk of recurrence after CBA in paroxysmal AF. ClinicalTrials.gov (NCT01360008), https://clinicaltrials.gov/ct2/show/NCT01360008.